More on CRBP
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $4.05 |
|
|||
| Open | $4.05 | ||||
| 52 Wk High | $10.78 | ||||
| 52 Wk Low | $1.01 | ||||
| Day High | $4.08 | ||||
| Day Low | $3.87 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 126,931 | ||||
- Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026
- Form 8-K Corbus Pharmaceuticals For: Oct 15
- Form SCHEDULE 13G Corbus Pharmaceuticals Filed by: RA CAPITAL MANAGEMENT, L.P.
- Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer
- Form 4 Corbus Pharmaceuticals For: Sep 14 Filed by: Ben Yong
- H.C. Wainwright Reiterates Buy Rating on Corbus Pharmaceuticals (CRBP)
- Form 8-K Corbus Pharmaceuticals For: Sep 14
- Corbus obesity drug hits 5% weight loss mark in phase 1b trial
- Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity
- Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity
Entities mentioned with CRBP
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- Jefferies & Co | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Show More...
